TD Cowen initiated coverage on Grace Therapeutics with a new price target
$GRCE
Biotechnology: Pharmaceutical Preparations
Health Care
TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $12.00 | Buy | TD Cowen |
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
4 - Grace Therapeutics, Inc. (0001444192) (Issuer)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
SCHEDULE 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
8-K - Grace Therapeutics, Inc. (0001444192) (Filer)
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company Intends to Resubmit Application Following Resolution of Cited Items PRINCETON, N.J., April 23, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that the U.S. Food and Drug Administ
PRINCETON, N.J., April 14, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that an abstract highlighting the results from the Company's STRIVE-ON Phase 3 Safety Trial has been accepted for presentation at the upcoming 2026 American Academy of Neurology annual meeting, to be held April 18-22, 2026 in Chicago, IL. The STRIVE-ON Trial results will be presented as a poster on A
PRINCETON, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous infusion to address significant unmet medical needs in aneurysmal subarachnoid hemorrhage (aSAH) patients, today announced that abstracts discussing the unmet medical needs and the potential benefits of GTx-104 have been accepted for presentation at two major medical conferences taking place in March 2026. The Company is participating in an industry education workshop during the Society of Critical Care Medicine's Critic
TD Cowen initiated coverage of Grace Therapeutics with a rating of Buy and set a new price target of $12.00
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)
SC 13G/A - Grace Therapeutics, Inc. (0001444192) (Subject)